ExoRNA Bio, a Shenzhen-based central nervous system (CNS) drug developer, has reportedly raised tens of millions of renminbi in an angel+ financing round. The round was led by Yuexiu Industrial Fund, with participation from Jingxin Pharma, Dingxin Capital, Nanjing University Biopharmaceutical Industry Alumni Association, and existing investor CDH Investments. The funds raised will be allocated towards the industrialization of the company’s technology platform and the IND filing for its first pipeline targeting Huntington’s disease.
Progress on Huntington’s Disease Pipeline and Technology Platform
Founded in 2022, ExoRNA Bio’s inaugural pipeline is focused on developing a treatment for Huntington’s disease, a rare autosomal dominant hereditary condition. The company has completed numerous animal efficacy and toxicology experiments and is preparing to file for orphan drug designation (ODD) in the US. ExoRNA Bio prides itself on its third-generation nucleic acid delivery technology platform, which is a key differentiator in the development of novel CNS treatments.
The Impact of Investment on ExoRNA Bio’s Growth
The investment secured by ExoRNA Bio is expected to accelerate the company’s growth, bolstering its efforts in technology platform industrialization and advancing its pipeline towards clinical development. This financing round not only validates ExoRNA Bio’s potential in the CNS drug development space but also underscores the investor confidence in the company’s approach to tackling complex neurological disorders.-Fineline Info & Tech
